Goldman Sachs Maintains Schrodinger(SDGR.US) With Hold Rating, Raises Target Price to $28
Schrodinger Is Maintained at Outperform by BMO Capital
Schrodinger Analyst Ratings
Craig-Hallum Maintains Schrodinger(SDGR.US) With Buy Rating, Announces Target Price $30
BMO Capital Maintains Schrodinger(SDGR.US) With Buy Rating, Raises Target Price to $28
A Quick Look at Today's Ratings for Schrodinger(SDGR.US), With a Forecast Between $25 to $33
KeyBanc Keeps Their Buy Rating on Schrodinger (SDGR)
Craig-Hallum Maintains Schrodinger(SDGR.US) With Buy Rating
Craig-Hallum Maintains Schrodinger(SDGR.US) With Buy Rating
BMO Capital Maintains Schrodinger(SDGR.US) With Buy Rating, Cuts Target Price to $25
Goldman Sachs Maintains Schrodinger(SDGR.US) With Hold Rating, Raises Target Price to $27
TD Cowen Maintains Schrodinger(SDGR.US) With Buy Rating, Maintains Target Price $42
TD Cowen Sticks to Its Buy Rating for Schrodinger (SDGR)
Schrodinger Analyst Ratings
Morgan Stanley Maintains Schrodinger(SDGR.US) With Hold Rating, Cuts Target Price to $30
Analysts Conflicted on These Healthcare Names: Medtronic (MDT) and Schrodinger (SDGR)
Craig-Hallum Maintains Schrodinger(SDGR.US) With Buy Rating
BofA Securities Maintains Schrodinger(SDGR.US) With Hold Rating
Analysts Conflicted on These Healthcare Names: Cencora (COR), Schrodinger (SDGR) and Biogen (BIIB)
TD Cowen Maintains Schrodinger(SDGR.US) With Buy Rating, Maintains Target Price $42